Pfizer Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Pfizer yıllık ortalama 3.5% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 13.3% annual. Gelirler growing yılda ortalama 0.9% oranında artmaktadır. Pfizer'in özkaynak karlılığı 16.5% ve net marjı 27.6%'dir.

Anahtar bilgiler

3.5%

Kazanç büyüme oranı

3.5%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	17.5%
Gelir büyüme oranı	0.9%
Özkaynak getirisi	16.5%
Net Marj	27.6%
Sonraki Kazanç Güncellemesi	14 Feb 2025

Yakın geçmiş performans güncellemeleri

Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)

May 25

Recent updates

We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its Debt

Aug 31

Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 25%

Aug 07

This Is The Reason Why We Think Pfizer Limited's (NSE:PFIZER) CEO Deserves A Bump Up To Their Compensation

Aug 12

Are Institutions Heavily Invested In Pfizer Limited's (NSE:PFIZER) Shares?

Mar 10

Why Dividend Hunters Love Pfizer Limited (NSE:PFIZER)

Feb 17

Gelir ve Gider Dağılımı

Pfizer nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NSEI:PFIZER Gelir, gider ve kazançlar (INR Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	22,381	6,179	4,425	0
30 Jun 24	22,247	6,085	3,457	0
31 Mar 24	21,932	5,513	4,337	0
31 Dec 23	22,192	5,021	3,998	0
30 Sep 23	23,010	5,228	4,021	0
30 Jun 23	23,632	6,849	3,948	0
31 Mar 23	24,248	6,239	3,935	0
31 Dec 22	24,041	6,201	4,334	0
30 Sep 22	24,583	6,133	4,514	0
30 Jun 22	24,571	4,452	4,762	0
31 Mar 22	26,110	6,126	4,784	0
31 Dec 21	25,961	5,873	4,720	0
30 Sep 21	25,137	5,847	4,564	0
30 Jun 21	24,728	5,731	4,353	0
31 Mar 21	22,404	4,976	4,266	0
31 Dec 20	22,058	5,001	4,555	0
30 Sep 20	21,505	4,979	4,514	0
30 Jun 20	21,221	5,208	3,628	0
31 Mar 20	21,517	5,091	4,531	0
31 Dec 19	21,853	5,156	4,628	0
30 Sep 19	21,609	5,085	4,565	0
30 Jun 19	21,136	4,500	4,483	0
31 Mar 19	20,815	4,291	4,416	0
31 Dec 18	20,658	4,241	4,377	0
30 Sep 18	20,085	3,794	4,196	0
30 Jun 18	20,599	3,947	3,142	0
31 Mar 18	19,685	3,601	4,210	0
31 Dec 17	18,866	3,236	3,911	0
30 Sep 17	19,215	2,987	4,130	0
30 Jun 17	18,860	3,139	3,090	0
31 Mar 17	19,663	3,368	4,086	0
31 Dec 16	20,453	2,737	4,452	0
30 Sep 16	20,595	2,711	4,357	0
30 Jun 16	20,350	2,276	4,237	0
31 Mar 16	20,123	3,050	4,068	0
31 Dec 15	19,649	1,680	5,755	0
30 Sep 15	19,334	1,460	5,603	0
30 Jun 15	19,018	861	5,583	0
31 Mar 15	18,531	698	3,594	0
31 Dec 14	16,632	1,137	4,199	9
30 Sep 14	11,078	1,380	3,817	9
30 Jun 14	11,118	2,194	1,722	0
31 Mar 14	11,103	2,209	3,936	0
31 Dec 13	11,161	2,230	4,163	79

Kaliteli Kazançlar: PFIZER yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: PFIZER 'nin mevcut net kar marjları (27.6%) geçen yılın (22.7%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: PFIZER şirketinin kazancı son 5 yılda yılda 3.5% oranında arttı.

Büyüme Hızlandırma: PFIZER 'un son bir yıldaki kazanç büyümesi ( 18.2% ) 5 yıllık ortalamasını (yıllık 3.5% ) aşıyor.

Kazançlar vs. Sektör: PFIZER geçen yılki kazanç büyümesi ( 18.2% ) Pharmaceuticals sektörünün 20.5% performansını geride bırakmadı.

Özkaynak Getirisi

Yüksek ROE: PFIZER 'nin Özsermaye Getirisi ( 16.5% ) düşük olarak değerlendiriliyor.

Pfizer Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2025 earnings released: EPS: ₹34.61 (vs ₹32.56 in 2Q 2024)

First quarter 2025 earnings released: EPS: ₹32.94 (vs ₹20.44 in 1Q 2024)

Pfizer Limited to Report Q1, 2025 Results on Jul 29, 2024

Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)

Full year 2024 earnings released: EPS: ₹121 (vs ₹136 in FY 2023)

Pfizer Limited to Report Q4, 2024 Results on May 17, 2024

Recent updates

Pfizer Limited Appoints Mr. Chetan Solse as India Legal Lead, Effective November 18, 2024

Pfizer Limited Announces Board and Committee Changes

Pfizer Limited Announces Executive Appointments, Effective November 7, 2024

Second quarter 2025 earnings released: EPS: ₹34.61 (vs ₹32.56 in 2Q 2024)

High number of new directors

We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its Debt

Pfizer Limited Approves to Declare A Dividend for the Financial Year Ended March 31, 2024

Dividend of ₹35.00 announced

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 25%

Price target increased by 11% to ₹5,477

First quarter 2025 earnings released: EPS: ₹32.94 (vs ₹20.44 in 1Q 2024)

Pfizer Limited to Report Q1, 2025 Results on Jul 29, 2024

Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)

Full year 2024 earnings released: EPS: ₹121 (vs ₹136 in FY 2023)

Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024

Pfizer Limited to Report Q4, 2024 Results on May 17, 2024

Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Pfizer (NSE:PFIZER) Has A Pretty Healthy Balance Sheet

Third quarter 2024 earnings released: EPS: ₹28.42 (vs ₹32.93 in 3Q 2023)

Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024

Pfizer Limited to Report Q3, 2024 Results on Feb 09, 2024

Pfizer Limited's (NSE:PFIZER) Business Is Yet to Catch Up With Its Share Price

Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023

Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023

Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors

Second quarter 2024 earnings released: EPS: ₹32.56 (vs ₹67.99 in 2Q 2023)

Pfizer Limited to Report Q2, 2024 Results on Oct 28, 2023

Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner Lead

Pfizer Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023

New major risk - Revenue and earnings growth

Pfizer Limited Announces Change in Management, Effective September 1, 2023

Pfizer Limited to Report Q1, 2024 Results on Aug 11, 2023

Upcoming dividend of ₹40.00 per share at 0.9% yield

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited, Annual General Meeting, Aug 18, 2023

Pfizer Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023

Pfizer Limited Initiates Voluntary Recall Of Magnex 1gm, 2gm, Magnex Forte 1.5gm, 3gm, Zosyn 4.5gm and Magnamycin 250mg, 1gm, 2gm Injections

Price target decreased by 7.9% to ₹4,595

Pfizer Limited Recommends A Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 16, 2023

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited to Report Fiscal Year 2023 Results on May 15, 2023

Here's Why Pfizer (NSE:PFIZER) Can Manage Its Debt Responsibly

Third quarter 2023 earnings released: EPS: ₹32.93 (vs ₹31.46 in 3Q 2022)

Pfizer India Appoints Meenakshi Nevatia as CEO

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Upcoming dividend of ₹30.00 per share

Pfizer Limited Announces Interim (Special) Dividend for the Financial Year Ending March 31, 2023, Payable on or Before September 30, 2022

Pfizer Limited Approves Declaration of Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹35.00 per share

Pfizer Announces Resignation of S. Sridhar as Managing Director

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

First quarter 2023 earnings released

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

Mylan Pharmaceuticals Private Limited completed the acquisition of off-patent branded and generic established medicines business from Pfizer Limited (BSE:500680).

Pfizer Limited to Report Q1, 2023 Results on Aug 05, 2022

A Look At The Intrinsic Value Of Pfizer Limited (NSE:PFIZER)

Now 20% undervalued after recent price drop

Price target decreased to ₹5,201

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: ₹134 (vs ₹109 in FY 2021)

Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2022, Payable on or before September 23, 2022

Price target decreased to ₹5,654

Insufficient new directors

Insufficient new directors